An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function.
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Trebananib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Amgen
- 11 Jan 2017 Results published in the Clinical Pharmacology and Therapeutics journal.
- 06 Feb 2014 Status changed to completed as reported by ClinicalTrials.gov.
- 18 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.